These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26728875)

  • 41. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
    Pujade-Lauraine E; Topham C
    Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
    Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
    Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
    Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
    Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Generic and biosimilar drug substitution: a panacea?].
    Daly MJ; Guignard B; Nendaz M
    Rev Med Suisse; 2015 Oct; 11(490):1909-12, 1914. PubMed ID: 26665661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) Study.
    Saragoussi D; Chollet J; Bineau S; Chalem Y; Milea D
    Int J Clin Pract; 2012 Nov; 66(11):1079-87. PubMed ID: 23067031
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacist Substitution of Biological Products: Issues and Considerations.
    Li E; Ramanan S; Green L
    J Manag Care Spec Pharm; 2015 Jul; 21(7):532-9. PubMed ID: 26108377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postmarket policy considerations for biosimilar oncology drugs.
    Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
    Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erythropoiesis-stimulating agents: development, detection and dangers.
    Franz SE
    Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
    Linton A; Bacon T; Peterson M
    J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 54. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
    Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
    Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
    Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
    BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.